Angela Jain is an Oncology physician affiliated with Fox Chase Cancer Center. OpenAlex indexes 47 publications with 1,727 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
333 Cottman Ave
Philadelphia, PA 191112434
Telephone
215-728-6900Registry record last updated 6 Sept 2013.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- KYOWA KIRIN, INC.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20253 payments
- Daiichi Sankyo Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
65.7%Aromatase Inhibitor35.9%Anastrozole65%Letrozole23%Exemestane12%Part D≥57 patientsKinase inhibitor20.4%Ibrance41%Verzenio30%Lenvima21%Mekinist8%Part D<11 patients+ 2 more classes in this area
Nervous system
17.6%Gabapentinoids4.8%Gabapentin100%Part D≥12 patientsAtypical Antipsychotic4.1%Olanzapine100%Part D≥25 patients+ 3 more classes in this area
Metabolism & gastrointestinal
9.5%Serotonin-3 Receptor Antagonist5.6%Ondansetron Hcl100%Part D≥34 patientsCorticosteroid2.5%Prednisone100%Part D≥12 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Elizabeth Plimack, MD
Fox Chase Cancer Center
Robert Uzzo, MD02041967
Fox Chase Cancer Center
John Ridge, MD
Fox Chase Cancer Center
Eric Horwitz, MD
Fox Chase Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”